Alterações no perfil lipídico durante o primeiro ano após o transplante renal: Fatores de risco e a influência do regime imunossupressor

• Autor(a) principal: Spinelli, Glaucio Amaral [UNIFESP]
• Data de Publicação: 2010
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://repositorio.unifesp.br/handle/11600/8887
• topic: Dyslipidemias; Hyperlipidemias; Immunosuppression; Kidney Transplantation; Imunossupressão; Transplante renal; Transplante de rim; Dislipidemias; Hiperlipidemias

Aim: Dyslipidemia is a recognized risk factor associated with cardiovascular events after kidney transplantation, Cyclosporine (CSA), tacrolimus (TAC), mycophenolate (MMF), sirolimus (SRL), everolimus (EVR) and prednisone have differential effects on the development of dyslipidemia, This study analyzed the incidence, time-course, severity and risk factors associated with dyslipidemia during the first year after kidney transplantation, Methods: In a cohort of 474 kidney transplant recipients [CSA/SRL (n=137), CSA/MMF (n=58), CSA/EVR (n=47), SRL/MMF (n=32), TAC/SRL (n=86), TAC/MMF (n=114)] we evaluated the influence of demographics, clinical ouCOLomes and statin use on lipid profile changes [total cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, non-HDL-C, COL/HDL-C, LDL-C/HDL-C, TG/HDL-C] during the first year after transplantation, Results: Lipid profile was within recommended ranges in 28% of patients pretransplant and in 10% at one year, with 27% of them receiving statins, LDL-C could not be measured due to high TG concentrations in 20% of patients, At one year, LDL-C < 100 mg/dl was observed in 31,8% of patients, Within this group around 35% of patients still showed lipid fractions or ratios outside recommended target concentrations, Age, gender, time on dialysis, new onset diabetes mellitus, use of CSA or SRL/EVR and dose of prednisone were independent risk factors associated with dyslipidemia at one year, Conclusion: One year after transplant dyslipidemia is almost universal, Modifiable risk factors include the type and dose of immunosuppressive drugs, he variable changes in all lipid fractions and ratios may limit proper therapeutic interventions.